Now showing items 1-2 of 2

A biological classification for Alzheimer's disease - amyloid, tau and neurodegeneration (A/T/N): results from the Argentine-Alzheimer's disease neuroimaging initiative

Allegri, Ricardo F.; Pertierra, Lucía; Cohen, Gabriela; Chrem Méndez, Patricio; Russo, María Julieta; Calandri, Ismael Luis; Bagnati, Pablo M.; Tapajóz, Fernanda; Clarens, Florencia; Campos, Jorge A.; Nahas, Federico E.; Surace, Ezequiel I.; Vázquez, Silvia E.; Sevlever, G. E. (Universidad de la Costa, 2019)

The aim of this study was to describe the A/T/N research framework classiﬁcation for AD in the Argentine ADNI cohort and to explore the prediction to develop dementia in a prospective two-year follow-up.
Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America

Allegri, Ricardo F.; Chrem Méndez, Patricio; Russo, María Julieta; Cohen, Gabriela; Calandri, Ismael Luis; Campos, Jorge A.; Nahas, Federico E.; Surace, Ezequiel I.; Vázquez, Silvia E.; Sevlever, G. E. (Universidad de la Costa, 2018-04-14)

Objective: This study aimed to investigate the role and prognosis of Alzheimer disease biomarkers in patients with mild cognitive impairment (MCI) at a memory clinic in Latin America. Methods: We studied 89 patients with ...

Envíos recientes

A biological classification for Alzheimer's disease - amyloid, tau and neurodegeneration (A/T/N): results from the Argentine-Alzheimer's disease neuroimaging initiative
...
Allegri, Ricardo F. | 2019

The aim of this study was to describe the A/T/N research framework classiﬁcation for AD in the Argentine ADNI cohort and to explore the prediction to develop dementia in a prospective two-year follow-up.

LEER
Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America
...
Allegri, Ricardo F. | 2018-04-14

Objective: This study aimed to investigate the role and prognosis of Alzheimer disease biomarkers in patients with mild cognitive impairment (MCI) at a memory clinic in Latin America. Methods: We studied 89 patients with MCI, 43 with Alzheimer-type dementia, and 18 healthy controls (matched for age, sex, and educational level) at our memory clinic (Instituto FLENI) in Buenos Aires, Argentina. Patients and controls underwent an extensive demographic, neurological, and neuropsychological assessment. All subjects underwent a brain MRI scan; FDG-PET scan; amyloid PET scan; apolipoprotein E genotyping; and cerebrospinal fluid concentrations of Aβ1-42, tau, and phosphorylated tau. Patients were categorised as positive or negative for the presence of amyloid pathology and neurodegeneration. Results: Amyloid pathology was observed in cerebrospinal fluid results in 18% of controls, 64% of patients with MCI, and 92% of patients with Alzheimer-type dementia. Suspected non–Alzheimer disease pathophysiology was found in 11% of controls, 6% of patients with MCI, and 8% of patients with Alzheimer-type dementia. At 30 months of follow-up, 45% of amyloid-positive patients with MCI and 20% of amyloid-negative patients with MCI showed progression to dementia. Conclusions: This study demonstrates biomarker-based MCI prognosis and supports its role in clinical decision-making in daily practice.

LEER

Browsing by Author "Nahas, Federico E."

A biological classification for Alzheimer's disease - amyloid, tau and neurodegeneration (A/T/N): results from the Argentine-Alzheimer's disease neuroimaging initiative ﻿

Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America ﻿

Envíos recientes

A biological classification for Alzheimer's disease - amyloid, tau and neurodegeneration (A/T/N): results from the Argentine-Alzheimer's disease neuroimaging initiative

Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America

A biological classification for Alzheimer's disease - amyloid, tau and neurodegeneration (A/T/N): results from the Argentine-Alzheimer's disease neuroimaging initiative

Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America